Wave Life Sciences Ltd Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
5-Yr Fwd EPS Growth
-0.4%projected annual EPS growth
Analyst Coverage
16analysts covering
FY EPS (est.)
-$1.11next fiscal year
Monitoring Framework
Key Performance Indicators
Cash and Cash Equivalents Quarterly544.6MTarget: Sufficient to fund operations into the third quarter of 2028
Quarterly Collaboration Revenue Quarterly38.2MTarget: Driven by GSK collaboration milestones and partner programs
Watch Items
- WVE-N531 New Drug Application (NDA) SubmissionTrigger: Submission of NDA to the FDA for accelerated approval in DMD exon 53 skippingAction: Monitor FDA acceptance of the filing and potential accelerated approval timeline
- WVE-006 Regulatory Feedback on Accelerated Approval PathwayTrigger: Receipt of FDA/regulatory feedback on accelerated approval pathway for AATDAction: Evaluate clinical development timeline adjustments and pivotal trial designs based on feedback
- WVE-007 Phase 2a INLIGHT Trial Initiation and Biomarker DataTrigger: Initiation of Phase 2a multidose portion in individuals with higher BMIAction: Assess body composition, visceral fat reduction, and muscle preservation metrics at 3-month assessment
- WVE-008 Clinical Trial Application (CTA) FilingTrigger: Filing of CTA for homozygous PNPLA3 I148M liver diseaseAction: Track transition of the second RNA editing program into clinical-stage development
Research as of 20 Jun 2026